ALLHAT in perspective: Implications to clinical practice and clinical trials

Medical Journal of Malaysia

Volumn 60, Issue 2, 2005, Pages 239-245

  Yusoff, Khalid ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

ALLHAT; Clinical practice; Clinical trials; Hypertension

Indexed keywords

AMLODIPINE; CHLORTALIDONE; LISINOPRIL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; AGED; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; DISEASE MANAGEMENT; HEART DISEASE; MALAYSIA; METHODOLOGY; STANDARD;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; DISEASE MANAGEMENT; HEART DISEASES; HUMANS; HYPERTENSION; MALAYSIA; RANDOMIZED CONTROLLED TRIALS;

EID: 24944538002     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic JAMA 2002; 288: 2981-97.
2. Singer GM and Setaro JF. The ALLHAT Study. Implications for the management of resistant hypertension. J Clin Hypertens (Greenwich) 2005; 7 (1): 31-32.
3. Chobanian AV, Bakris GL, Black HR, et al. and the national High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertens 2003; 42: 1206-52.
4. Wolz M, Cutler JA, Roccella EJ, et al. Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am J Hypertens 2000; 13: 103-104.
5. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000. A rising tide. Hypertens 2004; 44: 398-404.
6. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
7. Nawawi H, MN Idris, IM Noor, Karim N, Arshad F, Khan R, and Yusoff K. Current status of coronary risk factors among rural Malays in Malaysia. J Cardiovasc Risk 2002; 9: 17-23.
8. Yusoff K, Singh S, Sulaiman MD, Pit A, Yunus H, Nawawi H. Five year prevalence in coronary risk factors in rural Malaysia. Atherosclerosis 2002; 3 (Suppl): 241.
9. He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am 1997; 81: 1077-97.
10. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101-06.
11. Ezzati M, Lopez AD, Rodgers A, Vander HS, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-60.
12. Collins R, Peto R, Godwin J, McMahon S. Blood pressure and coronary heart disease. Lancet 1990; 336: 370-71.
13. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Prolonged differences in blood pressure. Lancet 1990; 335: 765-74.
14. Julius S. Trials of hypertension treatment. Am J Hypertens 2000; 13: 11S-17S.
15. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertens 2004; 43: 10-17.
16. Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk of heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analysis from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med 2002; 137: 313-20.
17. Houston M, Asher JR, Naftilan AJ, Hawkins RG. ALLHAT not all that it's cracked up to be: Review of the facts and the science. J Am Nutraceitical Assoc 2003; Vol 6 No 1.
18. Yusuf S, Sleight P, Pogue J, et al. Effects of a angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation study investigation. N Engl J Med 2000; 342: 145-53.
19. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
20. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting-enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-13.
21. Moser M, Lunn J. Responses to captopril and hydrochlorthiazide in black patients with hypertension. Am J Cardiol 1985; 56: 101H-104H.
22. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann InternMed 2003; 21: 1055-76.
23. Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD, et al. Validation of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT): participants assigned to doxazosin and chlorthalidone. Curr Control Trials Cardiovasc Med 1002; 3: 10-19.
24. Davis BR, Furberg CD, Wright JT, Cutler JA, Whelton P, for the ALLHAT Collaborative Rsearch Group. ALLHAT: Setting the record straight. Arch Intern Med 2004; 141: 39 -46.
25. Guidelines Subcommittee. 1999 World Health Organisation-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
26. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001; 86: 713-18.
27. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. New Engl J Med 2000; 342: 905-12.
28. Sowers JR, Bakris GL. Antihypertensive therapy and the risk fo type 2 diabetes mellitus. N Engl J Med 2000; 342: 969-70.
29. Brown MJ, Palmer CR, Castaigne A, deLeeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomsed to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
30. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-16.
31. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects, Hypertension. 2004; 43: 963-69.
32. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293 -302.
33. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-91.
34. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-2.
35. Pfeffer MA, Braunwald E, Moy LA, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669 -77.
36. Agodoa LY, Appel L, Bakris GL, et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effects of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-28.
37. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
38. The Long-Term Intervention with Pravastatin Group in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
39. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-07.
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
41. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolaemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002; 288: 2998-3007.
42. Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and everyday clinical practice: a generalizability issue. Can J Cardiol 2004; 20: 417-21.
43. Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertens 2000; 35: 1025-30.